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The human immunodeficiency virus type 1 protease plays a critical role in the proteolytic processing of
precursor polyproteins during virion maturation. Contradictory evidence has been obtained for a possible role
for the protease early after infection, i.e., during DNA synthesis and/or integration. We have reexamined this
question by using conditional mutants of the protease. In one set of experiments, protease mutants that confer
a temperature-sensitive phenotype for processing were used to assess the need for protease activity early after
infection. No significant difference from results with wild-type virus was seen when infections were carried out
at either 35 or 40&C. In a separate set of experiments, infections were carried out in the presence of a protease
inhibitor. In this case, both wild-type virus and a drug-resistant variant were used, the latter as a control to
ensure a specific effect of the inhibitor. Infection with either virus was not inhibited at drug concentrations that
were up to 10-fold higher than those needed to inhibit intracellular processing by the viral protease. The results
obtained by both of these experimental protocols provide evidence that the human immunodeficiency virus type
1 protease does not play a role early after infection.
The retroviral protease (PR) plays a central role late in the
replication cycle of the virus. Virus particles are assembled
largely from the Gag and Gag-Pro-Pol polyprotein precursors,
and the PR is responsible for cleaving these precursor proteins
into their mature forms (reviewed in reference 23). If PR
activity is blocked, either by mutation or with a specific inhib-
itor, virions are produced with unprocessed proteins and the
virus particles are noninfectious (2, 4, 5, 7, 8, 13, 16, 20, 25, 31,
33, 34).
Mature nucleocapsid cores of equine infectious anemia virus
have been purified (30). Incubation of this protein complex in
vitro results in the cleavage of the mature viral nucleocapsid
protein (NC) to smaller products (29). This observation raised
the possibility that such a cleavage mediated by the viral PR
occurs during the early phase of the replication cycle. Evi-
dence indicating a role for proteolytic cleavage has been ob-
tained by using PR-specific inhibitors to block the early steps of
human immunodeficiency virus type 1 (HIV-1) replication (3,
36). However, similar experiments with the PR-specific inhib-
itor Ro 31-8959 (saquinavir) failed to show an effect on the
early stages of infection (10), although higher concentrations
of this inhibitor were found to block infection (22).
We have reexamined the role of the HIV-1 PR early in
infection by using conditional mutants of the PR. In one set of
experiments, we used viruses containing mutations in the PR
that were shown previously to confer temperature sensitivity to
PR-mediated protein processing (19). In another set of exper-
iments, we used a virus containing two mutations that confer
reduced sensitivity to the PR inhibitor A-77003 (12). We com-
pared the infectivity of the mutant and wild-type viruses under
permissive and nonpermissive conditions, measuring the early
steps of replication by the MAGI cell assay (15). We found no
significant difference in infectivity under conditions of reduced
PR activity. Thus, our experiments do not indicate a role for
the viral PR during the early steps of replication.
MATERIALS AND METHODS
Cells and viruses. MAGI cells (15) were obtained from Michael Emerman.
Virus was generated from cloned viral DNA after transfection of purified DNA
into HeLa cells (32). In the experiments designed to test the effect of tempera-
ture on infectivity, virus was generated after transfection of HeLa cells at 358C.
The virus was grown in either CEM cells or CEMX174 cells, using RPMI 1640
containing 2 mM glutamine and 10% (vol/vol) fetal calf serum as the growth
medium. Virus infectivity in the culture supernatant was measured by the MAGI
cell assay as described previously (15). For this assay, the cells were infected at
approximately 40% confluence.
Mutant viruses were generated after the introduction of mutations into cloned
viral DNA. Mutations within the PR coding domain to change the valine codon
at position 56 to a glycine codon (V56G) or the proline codon at position 79 to
a threonine codon (P79T) were introduced separately into the HXB2 clone of
HIV-1 (27). The HXB2 clone was modified to remove the cellular sequences
flanking the 39 long terminal repeat. Mutations to alter the valine codon at
position 32 to an isoleucine codon (V32I) and the valine codon at position 82 to
an isoleucine codon (V82I) were introduced together into the NL4-3 clone of
HIV-1 (1) to create the V32I/V82I mutant. In each case, the presence of the
mutation in the full-length clone was confirmed by DNA sequence analysis.
Details of the cloning procedures are available on request.
Infections under nonpermissive conditions. In the experiments designed to
assess the effect of temperature on infectivity, cells were maintained at either 35
or 408C. These temperatures were chosen on the basis of the ability of CEM cells
to support wild-type virus replication at each of these temperatures (18a). In the
MAGI cell assay, cells were transferred from a 378C incubator to the indicated
temperature 3 h prior to infection and the infection was done with virus-con-
taining culture supernatants that had been prewarmed to the same temperature
as the cells.
The Abbott PR inhibitor A-77003 (14) was also used to assess the effect of an
inhibitor of the PR early after infection. In these experiments, cells were prein-
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cubated with various concentrations of inhibitor for the indicated time prior to
infection. The inhibitor was present during the 2-h exposure of cells to virus and
throughout the entire period after infection. The inhibitor was prepared at stock
concentrations up to 3 mM in dimethyl sulfoxide. The concentration of dimethyl
sulfoxide in the culture medium never exceeded 1%.
Analysis of viral proteins. For comparison of viral Gag polyprotein processing
at different temperatures, HeLa cells were transfected with wild-type or mutant
DNA clones of HIV-1 in duplicate 100-mm-diameter plates (11) and then incu-
bated at 378C for 18 h. At this time, the plates were placed at either 35 or 408C
and starved for 4 h in prewarmed Dulbecco’s modified Eagle’s medium with a
high concentration of glucose (4,500 mg/liter) without methionine. The cells
were then labeled with 100 mCi of [35S]methionine per ml in methionine-free
medium for 18 h at either 35 or 408C. At the end of the labeling period, the cells
were washed twice in ice-cold phosphate-buffered saline and scraped into 400 ml
of RIPA buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 50 mM
Tris [pH 7.5], 2 mg of leupeptin per ml, 1 mg of pepstatin A per ml, 100 mg of
phenylmethylsulfonyl fluoride per ml, 2 mg of aprotinin per ml). Nuclei and
cellular debris were pelleted by centrifugation of the extract at 3,000 3 g for 5
min. The supernatant fraction was incubated with human serum from an HIV-
1-infected individual. The serum had first been preabsorbed with an unlabeled
HeLa cell extract and then absorbed to protein A-Sepharose to collect the
antibodies from the unlabeled extract. The Sepharose-antibody complex was
incubated with the labeled extract from infected cells for 4 h, and then the
Sepharose-antibody-protein complexes were washed five times in washing buffer
(250 mM NaCl, 1% Nonidet P-40, 0.5% sodium dodecyl sulfate [SDS], 50 mM
Tris [pH 7.5], 2 mg of leupeptin per ml, 1 mg of pepstatin A per ml, 100 mg of
phenylmethylsulfonyl fluoride per ml, 2 mg of aprotinin per ml), resuspended in
50 ml of SDS sample buffer, heated to 1008C for 5 min, and loaded onto an
SDS–12% polyacrylamide gel. Following electrophoresis, the gel was fixed and
prepared for fluorography (En3Hance; DuPont). Radioactive analytic imaging
(AMBIS, San Diego, Calif.) was used to quantitate the relative amounts of
processed p24 capsid protein (CA) generated at 35 and 408C by the wild-type and
mutant viruses.
For Western blot (immunoblot) analysis, nearly confluent 100-mm plates of
MAGI cells were preincubated with A-77003 at various concentrations for 24 h.
The cells were then transfected with a molecular clone of either wild-type or
mutant HIV-1 DNA. The inhibitor was present during the transfection and until
the cells were harvested for Western blot analysis. At 48 h after the initial
transfection, the cells were washed four times with PBS; 100 ml of RIPA buffer
was then added to the plate, and the cells were scraped. Western blot analysis
with serum from an HIV-1-positive patient as the primary antibody was carried
out as described by Pettit et al. (26).
RESULTS
ts phenotype of PR mutants for processing. We have previ-
ously described a series of HIV-1 PR mutants that have a
temperature-sensitive (ts) phenotype for PR-mediated pro-
cessing of a linked Pol polyprotein domain when expressed in
Escherichia coli (19). The mutants showed a range of activity at
the permissive temperature and in each case showed a mod-
erate decrease in activity at the nonpermissive temperature
relative to the permissive temperature. We chose two of these
PR mutants, V56G and P79T, to characterize in the context of
HIV-1 replication. In the bacterial processing assay, the V56G
mutant showed very low processing at 378C and intermediate
processing at 328C; the P79T mutant showed near-wild-type
activity at 328C and intermediate activity at 378C (19). The
mutated PR coding domains were introduced into a full-length
infectious DNA clone of HIV-1, and a virus stock was gener-
ated for each mutant after transfection of the DNA into HeLa
cells. Both mutants produced virus particles after infection.
Infectious DNA clones were used in a transfection proce-
dure to express transiently the wild-type and mutant genomes
at either 35 or 408C in an effort to determine the extent of
processing in the mutant viruses at the different temperatures.
Viral proteins were labeled over an 18-h period, and then the
cell-associated viral proteins were isolated by immunoprecipi-
tation with a patient antiserum. The labeled proteins in the
immunoprecipitate were separated by polyacrylamide gel elec-
trophoresis and detected by autoradiography and radioactive
analytic imaging. Cells transfected with the wild-type virus
showed extensive processing of the Pr55Gag precursor and the
presence of the processing product p24CA at both tempera-
tures (Fig. 1, lanes c and d). A PR active-site mutant (D25A)
contained only unprocessed Pr55Gag precursor (lanes e and f).
The V56G mutant contained Pr55Gag at both temperatures,
but p24CA was clearly evident only at 358C (lanes g and h). The
P79T mutant contained Pr55Gag and p24CA at both tempera-
tures, but more p24 was evident at 358C (lanes i and j).
The amount of p24 in each lysate was compared at each
temperature. A correction was made based on the wild type,
which produced approximately twice as much labeled p24 at
358C as at 408C (Fig. 1, lanes c and d). After subtracting the
twofold difference seen with the wild type, we found that both
mutants produced more p24 at the lower temperature than at
the higher temperature. The V56G mutant produced 11 times
more p24 at 358C than at 408C, whereas the P79T mutant
produced twice as much. These results confirm the ts pheno-
type of these mutants.
We also documented the ts phenotype of these mutants by
producing virus particles at different temperatures and then
quantitating the amount of virus produced at each tempera-
ture. Quantitation of the infectious virus particles produced
from cells transfected at either temperature was performed by
the MAGI cell assay at 378C (15). In this assay, the early steps
of virus replication up through the expression of tatmust occur
to score as an infectious event. For the wild-type virus, more
infectious virus was present in the culture kept at the higher
temperature than at the lower temperature. After correcting
for the increase seen with the wild type, we found a reduction
in titer to one-fifth for the V56G mutant and a reduction to
one-half for the P79T mutant when particles were produced at
the higher temperature compared with those produced at the
lower temperature (data not shown). These results again con-
firm the ts phenotype of these mutants. However, the V56G
mutant virus failed to grow when the virus stock was passaged
in CEM cells. The P79T mutant virus grew poorly in CEM cells
at 378C, and we were unable to demonstrate a ts phenotype for
virus spread.
Effect of temperature on the ability of viruses encoding
mutant PRs to infect MAGI cells.Mutant and wild-type viruses
FIG. 1. ts proteolytic processing by two HIV-1 PR mutants. HeLa cells trans-
fected with wild-type or mutant HIV-1 DNA clones were labeled for 18 h at
either 35 or 408C. At the end of the labeling period, viral proteins were isolated
from cell lysates by immunoprecipitation followed by polyacrylamide gel elec-
trophoresis and fluorography. Lanes a, c, e, g, and i, labeling at 408C; lanes b, d,
f, h, and j, labeling at 358C; lanes a and b, mock transfection. Transfection was
carried out with the following HIV-1 DNA clones: wild type (lanes c and d), PR
active-site mutant (D25A) (lanes e and f), PR V56G mutant (lanes g and h), and
PR P79T mutant (lanes i and j). The positions of molecular mass markers are
shown on the left, and the positions of the Pr55Gag precursor and the p24CA
processing product are shown on the right.
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were produced after transfection of HeLa cells at 358C and
used immediately to infect MAGI cells at either 35 or 408C.
After a 3-h infection of the MAGI cells, the virus-containing
medium was removed and replaced with prewarmed medium.
The respective cultures were maintained for 2 days at the two
temperatures. At that time, the cells were stained to assess the
virus titer. In all cases, the virus titer was higher at 408C than
to 358C (Fig. 2). For the wild-type virus and the P79T mutant,
the increase in titer at the higher temperature compared with
the lower temperature was comparable, approximately sixfold.
The titer of the V56G mutant also increased at the higher
temperature, although in this case the increase was only three-
fold. Taken together, these results suggest that the higher
temperature had little to no effect on the ability of the mutant
viruses encoding a ts PR to carry out the early steps of virus
replication compared with the wild-type virus.
Protein processing of wild-type and mutant viruses in the
presence of a PR inhibitor. Previous studies have used PR
inhibitors to assess the role of the HIV-1 PR in the early
phases of virus replication, with disparate results (3, 10, 22, 36).
We sought to define an experimental protocol which would
allow us to document the effectiveness of the inhibitor on PR
activity and also modulate the sensitivity of the virus to the
inhibitor. We chose to infect MAGI cells with virus in the
presence of the PR inhibitor A-77003 (14) and to use either
wild-type HIV-1 or a mutant of HIV-1 that is partially resistant
to this inhibitor (12). If the viral PR is important during an
early step in replication, the inhibitor should block infection of
MAGI cells, and the two viruses should show different sensi-
tivities to the inhibitor.
In an effort to establish the effectiveness of the inhibitor and
the relative sensitivity of the two viruses to the inhibitor, we
examined the extent of proteolytic processing of viral proteins
expressed in MAGI cells. The cells were pretreated for 24 h
either with no A-77003 or with 0.1, 0.3, or 1.0 mM inhibitor.
The infectious viral DNA represented either the wild-type
genome or the mutant genome encoding the PR mutations
valine at position 32 to isoleucine and valine at position 82 to
isoleucine (V32I/V82I). The V32I/V82I mutant virus encodes
a PR that has a 20-fold increase in the Ki for A-77003 (12).
Inhibitor was maintained in the medium after the transfection.
Cells were harvested at 48 h after transfection, and cell-asso-
ciated viral proteins were examined by Western blot analysis.
The wild-type virus showed both Pr55Gag and p24CA in the
absence of inhibitor, with an excess of p24 (Fig. 3, lane b). At
0.1 mM A-77003, there was an increase in the amount of the
p25CA intermediate and of an approximately 40-kDa interme-
diate (lane c). At 0.3 mM inhibitor, very little p24CA was gen-
erated, and at 1.0 mM, only the Pr55Gag precursor was appar-
ent and all processed products were essentially absent (lanes d
and e). This experiment defined conditions in MAGI cells in
which all activity of the wild-type PR was lost, as measured by
processing of the Gag precursor.
The V32I/V82I mutant virus showed reduced sensitivity to
the inhibitor compared with the wild type. In the absence of
inhibitor, there was evidence of some incomplete processing
with the presence of the p25CA intermediate (Fig. 3, lane f).
However, this pattern was unchanged in the presence of either
0.1 or 0.3 mM inhibitor (lanes g and h). Only at the highest
concentration of inhibitor (1.0 mM) was there significant inhi-
bition of processing, and even here the inhibition was incom-
plete (lane i). Thus, as expected, the mutant was less sensitive
to the effects of the inhibitor.
Effect of a PR inhibitor on the infectivity of wild-type and
mutant viruses. We used the conditions defined in the trans-
fection experiment to assess the ability of a PR inhibitor to
block the initial steps of HIV-1 infection. Wild-type and V32I/
V82I mutant viruses were used to infect MAGI cells that had
been pretreated with inhibitor for 48 h. The inhibitor was main-
tained throughout the 48-h period after infection, at which
time the number of successful infectious events was deter-
mined at each drug concentration.
There were two considerations in choosing the inhibitor
concentrations. First, on the basis of the transfection experi-
ment, we expected that 0.3 mM inhibitor would block wild-type
PR activity but not mutant PR activity, and that 1.0 mM inhib-
FIG. 2. Effect of temperature on the infectivity of HIV-1 PR mutants. Virus
produced after transfection at 358C was used to infect MAGI cells at either 35 or
408C. At 2 days after infection, the cells were stained for the presence of
b-galactosidase activity (15) and the number of staining cells was quantitated. IU,
infectious units. Hatched bars, titer of virus after infection at 408C; solid bars,
titer of virus after infection at 358C; wt, wild type.
FIG. 3. Proteolytic processing by wild-type and mutant PR in the presence of
a PR inhibitor. MAGI cells were pretreated with various concentrations of the
HIV-1 PR inhibitor A-77003 and then transfected with a full-length HIV-1
infectious DNA representing either the wild-type genome (WT, NL4-3) or a
mutant with codons 32 and 82 of the PR coding domain encoding isoleucine
instead of valine (V32I/V82I). At 24 h after transfection, the cells were lysed and
the presence of viral proteins was assessed by Western blot analysis with serum
from an HIV-1-positive patient as the primary antibody. Lanes: a, cell lysate from
cells that were neither transfected nor treated with inhibitor; b to e, cells trans-
fected with the wild-type HIV-1 DNA; f to i, cells transfected with the V32I/V82I
mutant HIV-1 DNA. The cells were treated with the PR inhibitor as follows: no
inhibitor (lanes b and f), 0.1 mM inhibitor (lanes c and g), 0.3 mM inhibitor (lanes
d and h), and 1.0 mM inhibitor (lanes e and i). On the right are the positions of
the molecular mass markers, and on the left are the positions of the Pr55Gag
precursor and the p24CA processed product.
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itor would block both the wild-type and mutant PRs. There-
fore, infections were done in the presence of these concentra-
tions of inhibitor. We also considered the possibility that the
inhibitor would enter infected cells to a higher level than it
would enter uninfected cells, causing us to underestimate the
amount of inhibitor needed to effect PR inhibition. Thus, we
also tested inhibitor concentrations that were 10-fold higher
(3.0 and 10 mM); we chose not to use higher concentrations
because of concerns of low level toxicity. As seen in Table 1,
neither the wild-type virus nor the V32I/V82I mutant showed
any decrease in infectivity when the infection was done in the
presence of the PR inhibitor at concentrations between 0.1 and
10.0 mM. By contrast, zidovudine, which inhibits viral DNA
synthesis (21), significantly reduced infectivity in this assay.
These results show that in the presence of concentrations of
inhibitor at which PR activity is inhibited as measured in the
context of virus assembly and maturation late in the virus life
cycle, there is no inhibition of the early steps of virus replica-
tion. This was true for both the wild-type and mutant viruses.
As with the ts viruses, these results indicate no role for the PR
early after infection.
DISCUSSION
The retroviral PR plays a central role in the virus life cycle.
Viruses with mutations in the PR assemble noninfectious par-
ticles composed of unprocessed Gag and Gag-Pro-Pol precur-
sors (5, 8, 13, 16, 25, 33, 34). Thus, PR activity has a major
impact at a late step in the virus life cycle, during the assembly
and maturation of virus particles. The particle that is released
must carry out the early steps of virus replication (penetration,
DNA synthesis, and integration) in the absence of any addi-
tional viral proteins. The particle that is produced late in in-
fection must be competent to carry out all of the necessary
steps early after infection.
The viral proteins reverse transcriptase and integrase are
incorporated into the virion to be available for DNA synthesis
and integration, respectively, early after infection. The struc-
tural proteins encoded within Gag function both late (in as-
sembly) and early in the replication cycle, as shown by the
existence of Gag mutants that form virions but fail to proceed
through the early stages of replication (9, 17, 28, 35, 38, 40).
Like all of the proteins in the Gag and Gag-Pro-Pol precursors,
the PR is included in the budded virus particle (18, 37, 39) and
thus is presumably present, like reverse transcriptase and in-
tegrase, during the early stages of infection after carrying out
proteolytic processing during the preceding late stage of virion
assembly. The observation that the equine infectious anemia
virus PR cleaves its NC protein during incubation of virus
cores in vitro led to the suggestion that such a cleavage might
occur during the early stages of virus replication as a required
part of successful DNA synthesis and/or integration (29).
Evidence for a role for the HIV-1 PR early after infection
was obtained by using PR inhibitors to block the early steps (3,
36). However, contradictory results were obtained by other
workers (10), although these subsequent negative results were
attributed to the use of insufficient inhibitor (22). One concern
in interpreting results with inhibitors is the potential for tox-
icity that would reduce the ability of the cell to support virus
replication. Toxicity that would affect virus replication is likely
to be apparent at concentrations of inhibitor that are below the
levels that result in cell killing, making the choice of a cyto-
toxicity assay problematic.
On the basis of these considerations, we chose several ap-
proaches to address the question of the role of PR early after
infection. We used two viruses with mutations in the PR that
confer ts processing (Fig. 1) and found no significant effect of
carrying out the early stages of infection at an elevated tem-
perature (Fig. 2), a result that does not support a role for PR
early after infection. A limitation in this experiment is the
possibility that the ts phenotype is expressed during folding of
the PR and not on the folded enzyme. In this case, the pro-
duction of wild-type and mutant viruses at a permissive tem-
perature should result in equally infectious particles when
tested subsequently at either a permissive or nonpermissive
temperature. At this time, we do not know the basis for the ts
phenotype of these mutants and therefore cannot distinguish
between these two possibilities. Another limitation with this
genetic approach is that less enzyme activity may be needed
early after infection than that required during the late steps of
infection, when the effects of these mutations were assessed.
The alternative approach was to use a PR inhibitor during
the early steps of infection. We chose inhibitor concentrations
that blocked the intracellular processing of the Gag precursor
by PR and also used concentrations 10-fold higher to ensure
that we had established conditions under which the PR would
be inhibited. kon rates for protease inhibitors have been mea-
sured in the range of 107 s21 M21 (6, 24), so that we would
expect PR to bind inhibitor rapidly after entering the cells
which had been pretreated with inhibitor at micromolar levels.
As a control against potential toxic effects, we compared the
infectivity of a wild-type virus with that of a virus that has a
modest level of resistance to the PR inhibitor used (Fig. 3).
Our expectation was that if a decrease in infectivity were due
to toxicity, it would affect both viruses equally, but that if the
effect were due to inhibition of PR, the wild-type virus would
be more sensitive than the mutant. Over the range of inhibitor
concentrations used, we saw no decrease in infectivity with
either the wild-type or mutant virus (Table 1). This result
suggests that in these experiments, the PR inhibitor was not
toxic at the concentrations used and that it did not inhibit the
early steps of virus replication. It is difficult to reconcile these
negative results with the positive results previously published
(3, 22, 36) other that to raise concern over possible low levels
of cell toxicity at the concentrations of inhibitor that were used
previously. Our results, designed to validate the inhibitor con-
TABLE 1. Effect of a PR inhibitor on the early steps
of HIV-1 replication
Virusa
% Infectivity at A-77003 concn (mM) of b: % Infectivity
with AZT
(1.0 mM)0 (control) 0.1 0.3 1.0 3.0 10.0
Wild type
Expt 1 100 (120) 71 68 93 — — —
Expt 2 100 (1,680) —c 85 98 84 — 6
Expt 3 100 (1,353) — — — — 106 —
V32I/V82I
Expt 1 100 (169) 83 142 154 — — —
Expt 2 100 (924) 131 106 92 — — 14
Expt 3 100 (1,671) — 108 114 122 116 8
a Infections of MAGI cells were carried out with the indicated virus: wild type,
NL4-3; V32I/V82I, NL4-3 with two mutations in the PR coding domain.
b Cells were pretreated with the indicated concentration of A-77003 for 48 h
prior to infection, and the inhibitor concentration was maintained throughout
infection. The control infection was carried out in the absence of any inhibitor
treatment. The numbers in parentheses are the total numbers of blue cells
counted in the control well. The number of blue cells (infectious events) was set
at 100% for the infection in the absence of inhibitor. The number of infectious
events in the presence of inhibitor divided by the number in the control infection
in the absence of inhibitor times 100 is recorded as the percent value for the rest
of the infections.
c—, that this concentration of inhibitor was not included in the experiment.
VOL. 70, 1996 HIV-1 PROTEASE MUTANTS 5843
centration needed to inhibit PR intracellularly, showed no role
for PR activity early after infection.
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